Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

IDEAYA Biosciences (IDYA) Drug Pipeline

689 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Crizotinib, DarovasertibUveal MelanomaPhase IIIRecruitingStudy of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaAug 21, 2026―
Ide574, Fulvestrant InjectionNon-Small Cell Lung Cancer (Nsclc), Castration-Resistant Prostate Cancer (Crpc), Er+, Her 2- Breast Cancer, Microsatellite Stable (Mss) Colorectal CarcinomaPhase IRecruitingA Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsApr 01, 2026
Ide034Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Head And Neck Squamous Cell Carcinoma, Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Endometrium Cancer, High Grade Serous Ovarian Cancer, Castration-Resistant Prostate CancerPhase IRecruitingA Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesMar 19, 2026
Ide397, Ide892Bladder Cancer, Gastric Adenocarcinoma, Mesothelioma, Non-Small Cell Lung Cancer Nsclc, Pleural Mesothelioma, Gastroesophageal Cancer (Gc), Nsclc Adenocarcinoma, Adenocarcinoma Of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (Uc), Peritoneal MesotheliomaPhase IRecruitingA Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsNov 13, 2025
Ide849Small-cell Lung Cancerphase1AndPhase2RecruitingA Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerSep 11, 2025
Darovasertib, Primary Local TherapyUveal MelanomaPhase IIIRecruitingNeoadjuvant Darovasertib in Primary Uveal MelanomaJun 03, 2025―
Gsk4418959, Pd-1 InhibitorSolid Tumor, Endometrial Cancer, Rectal Cancer, Colon Cancer, Neoplasms, Colorectalphase1AndPhase2RecruitingA Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsNov 26, 2024―
Pembrolizumab, Nivolumab, Ipilimumab, Dacarbazine, Ide196, CrizotinibMetastatic Uveal Melanomaphase2AndPhase3RecruitingIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaJul 12, 2023
DarovasertibUveal MelanomaPhase IIRecruiting(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaJun 06, 2023―
Pembrolizumab, Ide-161Colorectal Cancer, Endometrial Cancer, Ovarian Cancer, Breast Cancer, Prostate Cancer, Nsclc, Head And Neck Cancers, Advanced Or Metastatic Solid TumorsPhase IRecruitingA Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsMar 17, 2023―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Ideaya Biosciences (IDYA) have in its pipeline
IDEAYA Biosciences IDYA is currently developing the following drugs: Crizotinib, Darovasertib, Ide574, Fulvestrant Injection, Ide034, Ide397, Ide892, Ide849, Darovasertib, Primary Local Therapy, Gsk4418959, Pd-1 Inhibitor, Pembrolizumab, Nivolumab, Ipilimumab, Dacarbazine, Ide196, Crizotinib, Darovasertib, Pembrolizumab, Ide-161, Sacituzumab Govitecan, Paclitaxel, Docetaxel, Ide397, Ide196, Binimetinib, Crizotinib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.